Literature DB >> 16988161

Management of extreme thrombocytosis in otherwise low-risk essential thrombocythemia; does number matter?

Ayalew Tefferi, Naseema Gangat, Alexandra P Wolanskyj.   

Abstract

Entities:  

Mesh：

Year:  2006        PMID： 16988161     DOI： 10.1182/blood-2006-05-025544

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  13 in total

Review 1.  Thrombosis in Philadelphia negative classical myeloproliferative neoplasms: a narrative review on epidemiology, risk assessment, and pathophysiologic mechanisms.

Authors:  Somedeb Ball; Kyaw Zin Thein; Abhishek Maiti; Kenneth Nugent
Journal:  J Thromb Thrombolysis       Date:  2018-05       Impact factor: 2.300

2.  Platelet count in essential thrombocythemia: the more the better?

Authors:  Ayalew Tefferi
Journal:  Blood       Date:  2008-10-15       Impact factor: 22.113

3.  Thrombocytosis and leukocytosis interaction in vascular complications of essential thrombocythemia.

Authors:  Alessandra Carobbio; Guido Finazzi; Elisabetta Antonioli; Paola Guglielmelli; Alessandro M Vannucchi; Federica Delaini; Vittoria Guerini; Marco Ruggeri; Francesco Rodeghiero; Alessandro Rambaldi; Tiziano Barbui
Journal:  Blood       Date:  2008-06-27       Impact factor: 22.113

4.  Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet.

Authors:  Tiziano Barbui; Giovanni Barosi; Gunnar Birgegard; Francisco Cervantes; Guido Finazzi; Martin Griesshammer; Claire Harrison; Hans Carl Hasselbalch; Rudiger Hehlmann; Ronald Hoffman; Jean-Jacques Kiladjian; Nicolaus Kröger; Ruben Mesa; Mary F McMullin; Animesh Pardanani; Francesco Passamonti; Alessandro M Vannucchi; Andreas Reiter; Richard T Silver; Srdan Verstovsek; Ayalew Tefferi
Journal:  J Clin Oncol       Date:  2011-01-04       Impact factor: 44.544

Review 5.  Polycythemia Vera.

Authors:  Jerry L Spivak
Journal:  Curr Treat Options Oncol       Date:  2018-03-07

Review 6.  JAK2 mutation and thrombosis in the myeloproliferative neoplasms.

Authors:  Alessandro M Vannucchi
Journal:  Curr Hematol Malig Rep       Date:  2010-01       Impact factor: 3.952

7.  Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial.

Authors:  Heinz Gisslinger; Mirjana Gotic; Jerzy Holowiecki; Miroslav Penka; Juergen Thiele; Hans-Michael Kvasnicka; Robert Kralovics; Petro E Petrides
Journal:  Blood       Date:  2013-01-11       Impact factor: 22.113

Review 8.  Insights into the pathogenesis and management of thrombosis in polycythemia vera and essential thrombocythemia.

Authors:  Alessandro M Vannucchi
Journal:  Intern Emerg Med       Date:  2009-09-30       Impact factor: 3.397

9.  Decisional flow with a scoring system to start platelet-lowering treatment in patients with essential thrombocythemia: long-term results.

Authors:  Roberto Latagliata; Angela Rago; Antonio Spadea; Cristina Santoro; Ida Carmosino; Massimo Breccia; Laura Napoleone; Angelo Fama; Francesca Biondo; Paola Volpicelli; Federico Vozella; Caterina Stefanizzi; Maria Concetta Petti; Giuliana Alimena; Maria Gabriella Mazzucconi
Journal:  Int J Hematol       Date:  2009-08-22       Impact factor: 2.490

10.  Phenotypic variability within the JAK2 V617F-positive MPD: roles of progenitor cell and neutrophil allele burdens.

Authors:  Alison R Moliterno; Donna M Williams; Ophelia Rogers; Mary Ann Isaacs; Jerry L Spivak
Journal:  Exp Hematol       Date:  2008-08-23       Impact factor: 3.084
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.